Your browser doesn't support javascript.
Maternal and perinatal outcomes following pre-Delta, Delta, and Omicron SARS-CoV-2 variants infection among unvaccinated pregnant women in France and Switzerland: a prospective cohort study using the COVI-PREG registry.
Favre, Guillaume; Maisonneuve, Emeline; Pomar, Léo; Daire, Charlotte; Poncelet, Christophe; Quibel, Thibaud; Monod, Cécile; Martinez de Tejada, Begoña; Schäffer, Leonhard; Papadia, Andrea; Radan, Anda Petronela; Todesco-Bernasconi, Monya; Ville, Yves; Voekt, Cora Alexandra; Eggel-Hort, Béatrice; Capoccia-Brugger, Romina; Johann, Silke; Grawe, Claudia; Defert, Sophie; Mottet, Nicolas; Kahlert, Christian R; Garabedian, Charles; Sentilhes, Loïc; Weber, Brigitte; Leu, Steffi; Bassler, Dirk; Lepigeon, Karine; Winterfeld, Ursula; Panchaud, Alice; Baud, David.
  • Favre G; Materno-fetal and Obstetrics Research Unit, Department "Femme-Mère-Enfant", University Hospital, Lausanne, Switzerland.
  • Maisonneuve E; Materno-fetal and Obstetrics Research Unit, Department "Femme-Mère-Enfant", University Hospital, Lausanne, Switzerland.
  • Pomar L; Institute of Primary Health Care (BIHAM), University of Bern, Bern, Switzerland.
  • Daire C; Materno-fetal and Obstetrics Research Unit, Department "Femme-Mère-Enfant", University Hospital, Lausanne, Switzerland.
  • Poncelet C; School of Health Sciences (HESAV), University of Applied Sciences and Arts Western Switzerland, Lausanne, Switzerland.
  • Quibel T; Materno-fetal and Obstetrics Research Unit, Department "Femme-Mère-Enfant", University Hospital, Lausanne, Switzerland.
  • Monod C; Department of Obstetrics and Gynecology, Pontoise Hospital, Pontoise, France.
  • Martinez de Tejada B; Department of Obstetrics and Gynecology, Poissy-Saint Germain Hospital, Poissy, France.
  • Schäffer L; Department of Obstetrics, Basel University Hospital, Basel, Switzerland.
  • Papadia A; Obstetrics Division, Department of Pediatrics, Gynecology and Obstetrics, Geneva University Hospitals, Faculty of Medicine, Geneva, Switzerland.
  • Radan AP; Division of Obstetrics, Baden Cantonal Hospital, Baden, Switzerland.
  • Todesco-Bernasconi M; Department of Gynecology and Obstetrics, Ente Ospedaliero Cantonale, Lugano, Switzerland.
  • Ville Y; Department of Obstetrics and Fetal-Maternal Medicine, University Hospital of Bern, University of Bern, Bern, Switzerland.
  • Voekt CA; Department of Obstetrics, Cantonal Hospital Aarau, Aarau, Switzerland.
  • Eggel-Hort B; Necker-Enfants Malades Hospital, Department of Obstetrics, Paris, France.
  • Capoccia-Brugger R; Department of Obstetrics, Grabs Hospital, Grabs, Switzerland.
  • Johann S; Obstetrics and Gynecology Unit, Sion Hospital, Sion, Switzerland.
  • Grawe C; Département de gynécologie-obstétrique, RHNE, Neuchâtel, Switzerland.
  • Defert S; Department of Gynecology and Obstetrics, Hospital of the Upper Valais, Visp, Switzerland.
  • Mottet N; Department of Obstetrics, Gynecology Stadtspital Triemli, Zürich, Switzerland.
  • Kahlert CR; Department of Gynecology, Mont-de-Marsan Hospital, Mont-de-Marsan, France.
  • Garabedian C; Department of Obstetrics and Gynecology, Besançon University Hospital, Besançon, France.
  • Sentilhes L; Infectious Diseases and Hospital Epidemiology, Children's Hospital of Eastern Switzerland, St. Gallen, Switzerland.
  • Weber B; Department of Obstetrics, CHU de Lille, Lille, France.
  • Leu S; Department of Obstetrics and Gynecology, Bordeaux University Hospital, Bordeaux, France.
  • Bassler D; Department of Obstetrics and Gynecology, Obwald Cantonal Hospital, Sarnen, Switzerland.
  • Lepigeon K; Department of Obstetrics and Gynecology, Nidwald Cantonal Hospital, Stans, Switzerland.
  • Winterfeld U; Neonatal Department, University Hospital Zürich, Zürich, Switzerland.
  • Panchaud A; Materno-fetal and Obstetrics Research Unit, Department "Femme-Mère-Enfant", University Hospital, Lausanne, Switzerland.
  • Baud D; Swiss Teratogen Information Service, Clinical Pharmacology Unit, Lausanne University Hospital and University of Lausanne, Switzerland.
Lancet Reg Health Eur ; 26: 100569, 2023 Mar.
Article in English | MEDLINE | ID: covidwho-2165667
ABSTRACT

Background:

SARS-CoV-2 positive pregnant women are at higher risk of adverse outcomes, but little evidence is available on how variants impact that risk. We aim to evaluate maternal and perinatal outcomes among unvaccinated pregnant women that tested positive for SARS-CoV-2, stratified by pre-Delta, Delta, and Omicron periods.

Methods:

This prospective study enrolled women from March 2020 to September 2022. Exposure to the different SARS-CoV-2 variants was defined by their periods of predominance. The primary outcome was severe maternal adverse outcome defined as either intensive care unit admission, acute respiratory distress syndrome, advanced oxygen supplementation, or maternal death. The secondary outcomes were preterm birth and other perinatal outcomes.

Findings:

Overall, 1402, 262, and 391 SARS-CoV-2 positive pregnant women were enrolled during the pre-Delta, Delta, and Omicron periods respectively. Severe maternal adverse outcome was reported in 3.4% (n = 947/1402; 95% confidence intervals (95%CI) 2.5-4.5), 6.5% (n = 7/262; 95%CI 3.8-10.2), and 1.0% (n = 4/391; 95%CI 0.3-2.6) of women during the pre-Delta, Delta, and Omicron periods. The risk of severe maternal adverse outcome was higher during the Delta vs pre-Delta period (adjusted risk ratio (aRR) = 1.8; 95%CI 1.1-3.2) and lower during the Omicron vs pre-Delta period (aRR = 0.3; 95%CI, 0.1-0.8). The risks of hospitalization for COVID-19 were 12.6% (n = 176/1402; 95%CI 10.9-14.4), 17.2% (n = 45/262; 95%CI 12.8-22.3), and 12.5% (n = 49/391; 95%CI 9.4-16.2), during the pre-Delta, Delta, and Omicron period, respectively. Pregnancy complications occurred after SARS-CoV-2 exposure in 30.0% (n = 363/1212; 95%CI 27.4-32.6), 35.2% (n = 83/236; 95%CI 29.1-41.6), and 30.3% (n = 105/347; 95%CI 25.5-35.4) of patients during the pre-Delta, Delta, and Omicron periods, respectively. Stillbirths were reported in 0.5% (n = 6/1159; 95%CI 0.2-1.1), 2.8% (n = 6/210; 95%CI 1.0-6.0), and 0.9% (n = 2/213; 95%CI 0.1-3.4) or patients during the pre-Delta, Delta, and Omicron periods respectively.

Interpretation:

The Delta period was associated with a higher risk of severe maternal adverse outcome and the Omicron period with a lower risk of severe adverse outcome compared to pre-Delta era. The reported risk of hospitalization was high during the Omicron period and should not be trivialized.

Funding:

Swiss Federal Office of Public Health, Fondation CHUV.
Keywords

Full text: Available Collection: International databases Database: MEDLINE Type of study: Cohort study / Experimental Studies / Observational study / Prognostic study Topics: Variants Language: English Journal: Lancet Reg Health Eur Year: 2023 Document Type: Article Affiliation country: J.lanepe.2022.100569

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Type of study: Cohort study / Experimental Studies / Observational study / Prognostic study Topics: Variants Language: English Journal: Lancet Reg Health Eur Year: 2023 Document Type: Article Affiliation country: J.lanepe.2022.100569